Advancing Therapeutics, Improving Lives Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases. Gilead’s primary areas of focus include: antivirals (such as HIV/AIDS and chronic hepatitis), cardiovascular conditions (such as pulmonary arterial hypertension and resistant hypertension) and respiratory diseases (such as influenza and cystic fibrosis). Our portfolio of 11 marketed products includes a number of category firsts and market leaders, including Atripla® - the first single tablet regimen for HIV infection. Gilead scientists invented the anti-influenza drug Tamiflu® (oseltamivir), which is marketed globally by Hoffmann-La Roche. The company's latest therapy, Letairis® (ambrisentan), was approved in June 2007 and is a once-daily oral treatment for pulmonary arterial hypertension (PAH). PAH is a progressive, life-threatening disease for which new therapies are urgently needed.

20 Years of Growth Gilead was founded in 1987 in Foster City, California. In just 20 years, Gilead has become one of the largest biopharmaceutical companies in the world, with a rapidly expanding product portfolio, growing pipeline of investigational drugs, more than 3,400 employees and operations on three continents. In 2007, Gilead annual revenues surpassed $4 billion. BusinessWeek magazine ranked Gilead third in its 2007 list of the Top 50 best-performing companies.